GlassScriptPhysician profile
Luis Egelsee
NPI 1407969140
$7,866.62
in general payments reported to CMS, 2019-2025
50 companies · $1,349 in 2025
The $1,349 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $433 · 2020: $598 · 2021: $1,269 · 2022: $1,091 · 2023: $1,470 · 2024: $1,657 · 2025: $1,349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,474.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,714.20 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $871.30 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $824.01 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $390.77 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.40 | 2020-2025 | Jardiance |
| Pfizer INC. | $346.21 | 2023-2025 | |
| Amgen INC. | $316.41 | 2021-2025 | Otezla, Repatha, Evenity |
| Corium, LLC | $302.05 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $277.00 | 2019-2024 | Trintellix |
| Glaxosmithkline, LLC. | $260.77 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Abbott Laboratories | $156.82 | 2021-2024 | Proclaim, Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $139.88 | 2022-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $123.54 | 2020-2023 | Xyosted, Qelbree, Tlando |
| Exact Sciences Corporation | $122.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $116.45 | 2020-2021 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Egelsee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.